Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma (KS), a tumor of endothelial origin predominantly affecting immunosuppressed individuals. Up to date, vaccines and targeted therapies are not available. Screening and identification of anti-viral compounds are compromised by the lack of scalable cell culture systems reflecting properties of virus-transformed cells in patients. Further, the strict specificity of the virus for humans limits the development of in vivo models. In this study, we exploited a conditionally immortalized human endothelial cell line for establishment of in vitro 2D and 3D KSHV latency models and the generation of KS-like xenograft tumors in mice. Importantly, the invasive properties and tumor formation could be completely reverted by purging KSHV from the cells, confirming that tumor formation is dependent on the continued presence of KSHV, rather than being a consequence of irreversible transformation of the infected cells. Upon testing a library of 260 natural metabolites, we selected the compounds that induced viral loss or reduced the invasiveness of infected cells in 2D and 3D endothelial cell culture systems. The efficacy of selected compounds against KSHV-induced tumor formation was verified in the xenograft model. Together, this study shows that the combined use of anti-viral and anti-tumor assays based on the same cell line is predictive for tumor reduction in vivo and therefore allows faithful selection of novel drug candidates against Kaposi's sarcoma.
Introduction
Up to 15% of human cancers are induced by oncogenic viruses [1] . One of the common oncogenic viruses is human herpesvirus 8 (HHV8), also known as Kaposi's sarcomaassociated herpesvirus (KSHV). KSHV causes to at least three human malignances, namely, Kaposi's sarcoma (KS), primary effusion lymphoma, and the plasma cell variant of multicentric Castleman's disease. Kaposi's sarcoma is a tumor of endothelial origin, often manifesting itself in the skin, but also affecting the liver, lungs, gastrointestinal tract, and lymph nodes. While the prevalence of KSHV in the population varies geographically, with less than 10% in Northern Europe and > 40% in Sub-Saharan Africa (reviewed in [2] ), the tumor mainly occurs in immunocompromised or elderly patients. It is the most common neoplasm in untreated AIDS patients and in men in Sub-Saharan Africa, as well as one of the most common malignancies in patients after organ transplantation [3] . Standard treatment options of Kaposi's sarcoma include surgery, chemotherapy, and irradiation therapy. The response of HIV-positive patients with Kaposi's sarcoma to these therapies ranges from 22 to 80%. Nevertheless, complete remission is rarely achieved [4] .
Rapamycin, a natural product from Actinobacteria, has emerged as a therapeutic compound of benefit for transplantation-associated KS and was shown to have antiangiogenic effects in a murine tumor model [5] . Several studies also suggest a selective sensitivity of KSHV-infected cells to rapamycin, as its molecular target mTOR is crucial for the survival of KSHV-infected cells and viral pathogenesis [6, 7] . This is in line with the observation that after renal transplantation in KSHV-infected patients, the replacement of standard immunosuppressive drugs with rapamycin resulted in a reduction of Kaposi's sarcoma lesions [8] . However, rapamycin cannot be used as a standard therapy for Kaposi's sarcoma, since it is an immunosuppressive agent and suppression of the immune system is a key factor of Kaposi's sarcoma's development. This highlights the need for novel anti-viral and antitumor agents.
KSHV-infected endothelial cells acquire spindle-like morphology [9] and undergo transcriptional reprogramming, referred to as endothelial-to-mesenchymal transition (EndMT) [10] . Most of the KSHV-positive cells are latently infected, and only a small proportion of the infected cells undergo lytic reactivation [11, 12] . Recently, several treatment options were suggested that target lytic reactivation of the virus (reviewed in [13] ), whereas targeting the predominant latent stage is still a challenge.
The investigation of the viral pathogenesis and identification of potential anti-viral compounds are compromised by the lack of scalable and robust in vitro models that reflect the virus-induced changes observed in vivo. Moreover, due to the restricted host tropism of KSHV, small animal models have not been available so far. Murine gamma-2 herpesvirus 68 (MHV-68) was proposed as a model to mimic KSHV infection in the mouse [14] . Similarly to KSHV, it establishes latent infection in B cells, which may lead to lymphoproliferative pathology [15, 16] . However, MHV-68 fails to establish tumors of endothelial origin and therefore cannot be used as a small animal model for Kaposi's sarcoma.
We recently described conditionally immortalized human endothelial cells (HuARLTs) that are permissive for KSHV infection [17, 18] . The cell line preserves the important properties of primary endothelial cells in vitro and gives rise to functional blood vessels when transplanted into mice. After infection with KSHV, the cells become spindle-like, lose endothelial properties, and undergo transcriptional changes corresponding to EndMT, thereby reflecting the features as described for patients. Upon transplantation into immunocompromised mice, the infected cells form lesions, histologically mimicking the lesions seen in Kaposi's sarcoma patients [18] . These properties suggest that this cell culture system may be suitable not only for the investigation of KSHV infection mechanisms but also for the validation of novel compounds.
Similar to other herpesviruses, the KSHV genome adopts an episomal, circular state in infected cells with a range of viral loads. Recently, it has been reported that the viral load in skin lesions correlates with disease severity [19] . The results of the aforementioned study suggested that drugmediated reduction of the viral copy number might allow to reduce tumorigenicity of cells.
In the current study, we established 2D and advanced 3D cell culture assays based on KSHV-infected endothelial HuARLT cells to screen a subset of 26 compounds from a natural compound library for reducing the episomal viral copy number and the tumorigenic properties (sprouting activity) of KSHV-infected cells in in vitro cell culture systems. Selected compounds were subsequently tested for the ability to reduce the tumor size in xenotransplanted mice. Our analysis shows that the 3D sprouting activity correlates with tumor size observed in vivo. Importantly, we could prove that tumor formation in vivo depends on KSHV infection and is reverted when the virus is purged from these cells. Together, this endothelial cell system allows not only the identification of novel compounds that reduce viral load and/or tumorigenicity in vitro but also the validation of compounds against KS-like lesions in xenograft mice.
Materials and methods

Cell culture
Human conditionally immortalized endothelial cells (HuARLTs) were generated in the lab of D. Wirth by lentiviral transfer of a doxycycline controlled SV40 large T antigen and hTert expression cassette as described before [17] . In 2D culture conditions, these cells proliferate in presence of 2 μg/ml doxycycline while they stop proliferation in absence of doxycycline. The cells form 3D spheroids that can be maintained in presence of doxycycline without an increase of cell number [17, 18] . rKSHV-HuARLT cells [18] were derived upon infection of HuARLTs with recombinant KSHV.219 carrying the constitutively expressed GFP and puromycin selection genes as well as RFP under control of a viral lytic promoter [20] .
HuARLT and rKSHV-HuARLT cells were cultivated on plates coated with 0.5% gelatin (G1393-100ML, Sigma) in endothelial growth medium (EGM, CC-3124, Lonza) in a humidified normoxic atmosphere with 5% CO 2 in the presence of 2 μg/ml doxycycline. Maintenance cultures of rKSHV-HuARLT cells additionally contained 5 μg/ml puromycin, while all the experiments were performed in the absence of the selection drug.
Cell viability and determination of drug concentrations
To assess cell viability upon treatment with standard drugs, rKSHV-HuARLT cells and HuARLT cells were seeded in 96-well plates (5000 cells/well) and incubated with 1.25 mg/ml rapamycin, 1.25 mg/ml FK506, 10 μM BAY11-7085, or 12.5 μM LY294002 for 72 h in absence of doxycycline. The maximal concentration of the solvent did not exceed 0.5% of the total volume. Cell viability was measured using the WSTbased Cell Counting Kit 8 (Sigma 96992-500TESTS-F) according to the manufacturer's instructions. In brief, cells were incubated with 100 μl of fresh media and 10 μl of the WST-8 solution at 37°C for 2-4 h followed by absorbance measurement at 450 nm using TriStar 2 LB 942 Modular Multimode Microplate Reader (Berthold Technologies). To calculate cell viability, the background values were subtracted and the data was normalized to DMSO-treated control values.
To determine the appropriate concentration for the new drugs, at least 4 concentrations per compound with 3 replicates were tested for cell viability. The drug concentrations that resulted in at least 80% viability are summarized in Supplementary Table 1 and were used for further experiments.
Spheroid production 4000 rKSHV-HuARLT cells per well were seeded on a 0.5% agarose-coated 96-well plate and cultivated at 37°C in a humidified normoxic atmosphere with 5% CO 2 in presence of doxycycline. After 24 or 48 h, the formed aggregates (spheroids) were harvested and embedded either in a fibrin gel (which supports spheroid sprouting) or in a Matrigel matrix (which provides robust matrix stability for extended cultivation times as required for copy number analysis).
Viral copy number analysis
2D cultures rKSHV-HuARLT cells were seeded on a 12-well plate (1 × 10 5 cells/well) and treated with the test compounds in absence of doxycycline and puromycin for 14 days.
3D cultures For every well, 6 to 8 spheroids were mixed with 0.7 mg/ml fibrin (341576, Calbiochem), 0.4% methylcellulose (M0512, Sigma), and 0.5 U/ml thrombin (605190-100U, Merck Millipore) in EGM medium supplemented with 2 μg/ml doxycycline. Matrigel (growth factor reduced, 354230 Becton Dickinson) was added to the spheroid mixture in a ratio of 1:1. 100 µl of the gel was cast into a 96-well and allowed to solidify for 30 min at 37°C. 100 µl of EGM supplemented with selected compounds was added on top of the gels (the concentration of compounds is given in Supplementary Table 1) .
Media were changed and fresh compounds were added to the media every 3-4 days in both 2D and 3D cultures. After 14 days of treatment, DNA was isolated from cells cultured under 2D or 3D culture according to a protocol described before [21] . Briefly, the cells were lysed using modified Bradley's buffer with proteinase K (19133, Qiagen) at 55°C overnight. Cellular DNA was precipitated in 75 mM sodium acetate in 96% ethanol solution. The pellet was washed with 70% ethanol, dried, and suspended in nuclease-free water. qPCR was performed at 58°C annealing temperature using SsoFast ™ EvaGreen ® Supermix (1725204, Bio-Rad) in a LightCycler 480 II (29376, Roche). The data were analyzed using LightCycler 480 software 1.5. Viral DNA was detected using LANA-specific primers and normalized to cellular DNA detected by the ACTB-specific primer pair (Supplementary Table 2 ). The number of viral copies per cell was extrapolated using a modified ΔCp method, taking into account that the cellular genome harbors 2 copies of the ACTB gene:
Spheroid sprouting assay
Spheroids from rKSHV-HuARLT cells were embedded in fibrin gels according to a protocol described in [10] . 6 to 8 spheroids were mixed with in fibrin solution (3 mg/ml) supplemented with 2 U/ml thrombin, 2 μg/ml doxycycline, and 0.25% methyl cellulose in Hanks' Balanced Salt Solution (088HBSS-500, Tebu-Bio). The mixtures were cast onto a 96-well and allowed to solidify for 30 min at 37°C. The respective compounds were added in EGM media using the concentrations listed in Supplementary Table 1 and incubated for 5 days. Quantification of spheroid sprouting was performed from fluorescence microscopy images using ImageJ software [22] . To this end, the area covered by sprouts at the representative focus plane was measured and normalized against the spheroid's core area (sprouting index).
Viral gene expression (RT-qPCR)
Total RNA was isolated from 5 × 10 5 rKSHV-HuARLT cells using RNeasy mini kit (74106, Qiagen) according to the manufacturer's instructions and measured with the ND-1000 spectrophotometer (NanoDrop Technologies). cDNA was synthetized from 500 ng of RNA using Reverse-Aid First Strand cDNA Synthesis Kit (K1622, Fisher Scientific) according to the manufacturer's instructions. Quantitative PCR was performed as described above using the primers specified in Supplementary Table 3 . Relative expression of viral genes in relation to cellular ACTB was calculated using the standard ΔCp method.
Natural compound library and screening of natural compound library against KSHV lytic replication
The natural compounds used in this study have been compiled at the Helmholtz Center for Infection Research and the Helmholtz Institute for Pharmaceutical Research Saarland in a ready-to-screen library that is available for screenings to evaluate their utility in various biological assays. The chemical synthesis of pretubulysin D was described before [23] . For assays on endothelial cells, we specifically selected derivatives from active compound classes that are feasible for in vivo studies due to availability and overall better characterization in terms of biological effects in other in vitro and in vivo experiments.
Brk.219, a BJAB cell line stably infected with rKSHV.219 [24, 25] , was used to screen a library of 260 natural compounds. Brk.219 cells were seeded into round-bottom 96-well plates at a density of 10 5 cells per well in 100 μl RPMI medium. Compounds were added at a final concentration of 10 μM, and the viral lytic cycle was induced by the addition of an antibody to human IgM on the BJAB cell surface as described [24] . 48 hours later, the supernatant of individual wells was collected and used to infect HEK293 cells. After a further 48 h, the number of GFP-positive HEK293 cells was quantified by a BioTek fluorescence reader. The viability of the treated Brk.219 cells was determined by MTT assay.
All compound tests on rKSHV-HuARLT cells were performed in non-proliferating cells. In particular, 2D culturebased tests on rKSHV-HuARLT cells were performed in absence of doxycycline and in absence of puromycin. As shown before, long-term cultures of rKSHV-HuARLT cells in 3D require the presence of doxycycline, which does not lead to proliferation but rather is required for maintenance of spheroids over time [18] . Accordingly, compound tests in 3D cultures were performed in presence of doxycycline.
Flow cytometry
× 10
5 rKSHV-HuARLT or HuARLT cells were washed and detached with trypsin/EDTA and resuspended in PBS supplemented with 2% FCS. Flow cytometric analysis was performed on a FACSCalibur ™ analyzer (Becton-Dickinson).
Non-infected cells were used as a negative control. The data were processed with FlowJo v10 software.
Immunofluorescence microscopy rKSHV-HuARLT cells were plated on 0.5% gelatin-coated cover glass slips and fixed for 20 min with 4% formaldehyde in PBS followed by permeabilization with 0.5% Triton X-100 in PBS for 10 min. Blocking of the samples was done in PBS supplemented with 2% BSA for 1 h. The coverslips were stained with mouse monoclonal anti-LANA (NCL-HHV8-LNA, Leica) antibodies in PBS with 0.1% saponin Quillaja sp. (S4521, Sigma) at 4°C overnight. Staining with Cy3-labeled secondary goat anti-mouse antibodies (Dianova) was performed in PBS with 0.1% saponin at RT for 1 h. Coverslips were mounted on glass slides with Fluoroshield ™ containing DAPI (F6057-20ML, Sigma) and incubated at room temperature overnight. Images were acquired using a Zeiss LSM META confocal laser scanning microscope. Brightness and contrast were adjusted using ImageJ software.
Mouse experiments
rKSHV-HuARLT cells were transplanted to mice as described before [18] . In brief, 1.2 × 10 6 cells were seeded into each well of AggreWell ™ 400 (27945, Stemcell Technologies), centrifuged for 3 min at 100g, and cultivated for 3 days at 37°C. 400 spheroids were used for each Matrigel implant containing 0.2% methyl cellulose, 3 mg/ml fibrinogen in EGM media supplemented with 10 μg/ml FGF (100-18B-250, PeproTech), 0.5 μg/ml VEGF (RCPG246, Randox), 1 U/l thrombin (605190-100 U, Merck Millipore), and 300 μl of Matrigel HC (high protein, growth factor reduced, 354263, Becton Dickinson). The mixture was injected subcutaneously to Rag2
One milligram per milliliter of doxycycline was added to the drinking water for the whole experiment.
Starting from day 1 after implantation, the mice were treated with the drugs according to the route, dose, and regime adapted from previous studies (Supplementary Table 3 for  details) .
Animal experiments were performed in accordance with the ethical laws and were approved by the local authorities (permission number 33.19-42502-04-17/2480).
Immunohistological staining
After 4 weeks of treatment, Matrigel implants were extracted and fixed with 4% formalin, embedded in paraffine, sectioned, and stained with hematoxylin-eosin. Diameters of the lesions were measured on histological sections, stained for human vimentin. Human endothelial cells were marked applying in situ hybridization technique (ALU) and immunohistochemistry. The ALU probe was purchased from Ventana/Roche Diagnostics GmbH applying Ventana ISH detection kit. The following antibodies and dilutions were applied in order to mark the atypical endothelial cells using the BenchMark Ultra staining machine (purchased from Roche): antibody against CD141 (Serotec, 1:40), CD34 (Immunotech, 1:50), GFP (Santa Cruz Biotechnology Inc.; 1:10), HHV8 (LANA) (Novocastra/Menarini; 1:30); vimentin (Dako; 1:100).
Results
KSHV establishes latency in conditionally immortalized human endothelial cells
In order to develop assays for the identification of novel therapeutic agents against KSHV, we employed HuARLT cells, which maintain the properties of endothelial cells and which are characterized by doxycycline-dependent growth in 2D culture conditions [18] . Infection with rKSHV.219 encoding puromycin acetyl transferase and GFP [20] allowed for the selection and monitoring of infected cells. If cultivated under selection pressure, the rKSHV.219-infected HuARLT cells (rKSHV-HuARLT) display the characteristic spindle-like morphology and show punctuated localization of the latency-associated nuclear antigen (LANA) in the nuclei, indicating the association of viral episomes with the cellular chromosomes (Fig. 1a) . To investigate viral maintenance in the absence of selection, rKSHV-HuARLT cells were cultured in 2D culture conditions in absence of doxycycline and puromycin, followed by flow cytometry analysis of GFP expression. Under these conditions, GFP expression only slowly declined over time, with nearly 80% of cells still being positive for GFP after 16 days (Fig. 1b) . At the same time, viral DNA decreased from 9.19 ± 1.88 to 4.61 ± 0.61 copies per cell as determined by qPCR (Fig. 1c) , indicating loss of viral copies during cultivation.
In order to determine the predominant state of the viral life cycle in infected rKSHV-HuARLT cells, we evaluated the expression level of prototypic latent and lytic genes relative to cellular ACTB using RT-qPCR. The infected cells showed elevated levels of latent mRNAs, such as LANA, vCyclin, vFLIP, and Kaposin, whereas mRNAs of viral lytic genes, such as PAN, K-bZIP, ORF50, and ORF45, were expressed at lower levels or not at all, indicating that the infected cells had established latency (Fig. 1d) .
The crucial role of various cellular signaling pathways was previously highlighted for survival of virus-infected cells [26] . To confirm the relevance of these pathways in the established cell system, we investigated the viability of infected cells upon inhibition of the respective pathways. We observed differential cell viability upon treating infected and non-infected cells with rapamycin, BAY11-7085, and LY294002, i.e., agents that block mTOR, NF-kB, and PI3K pathways, respectively (Fig. 1e) . FK506, which is structurally related to rapamycin and shares a number of molecular targets with it, except for mTOR, was used as a negative control in this assay. In agreement with previous studies in primary cells [26] , these data suggest that mTOR, PI3K, and NF-kB pathways are important for survival of KSHV-infected HuARLT cells.
In conclusion, these results indicate that KSHV-infected HuARLT cells reflect the status of virus-infected cells in vivo and represent a valid model to identify novel active compounds.
Purging cells from virus abolishes the tumorigenic phenotype
We asked if the loss of the viral genome could revert the phenotype of infected cells and abrogate tumor formation in vivo. To this end, we expanded rKSHV-HuARLT cells for 38 days in presence of doxycycline but without puromycin. Following the prolonged cultivation, GFP-negative cells were isolated by FACS (designated as KF-HuARLT cells, Fig. S1 ). Analysis of the viral copy number in KF-HuARLT cells confirmed a significant reduction of viral genomes down to 0.07 ± 0.04 copies per cell indicating the absence of the KSHV genome in the vast majority of these cells (Fig. 1c) .
To investigate the tumor potential of KF-HuARLT cells, KF-HuARLT cells as well as the control rKSHV-HuARLT and HuARLT cells were aggregated to spheroids and transplanted into immunocompromised Rag2 −/− γc −/− mice according to a previously described protocol [18] (Fig. 2a) . After 4 weeks, the plugs were isolated. Sections were stained for human vimentin and the morphology of transplanted cells was examined via microscopy. The virus-infected rKSHVHuARLT cells formed lesions that were positive for virusencoded GFP and LANA as well as for human ALU sequences (Fig. 2b) . Further, the lesions were characterized by spindle cells as well as expression of human CD141 (thrombomodulin) which is found on Kaposi's sarcoma cells [27] , together reflecting the early patch stage of human KS (Fig. 2b) . In contrast, transplantation of KF-HuARLT cells resulted in engraftment of individual cells; however, no KSlike lesion could be found (Fig. 2c) . Thus, elimination of viral genomes from KSHV-infected HuARLT cells completely reverted the tumorigenic phenotype and impaired the formation of lesions indicating that continuous expression of KSHV genes is crucial for tumor formation. Further, this raises the hypothesis that the reduction of viral copy number might be a useful parameter to identify anti-tumor compounds.
Establishment of in vitro assays for compound validation
We evaluated the drug-induced reduction in viral load upon culturing the rKSHV-HuARLT cells in 2D culture conditions for 14 days in the absence of puromycin. To validate the loss of the episomal viral copies as a readout for anti-viral drug selection, we used glycyrrhizic acid (GA). GA downregulates LANA, the protein responsible for tethering viral episomes to the cellular genome, and thereby reduces the viral load of infected cells [28] . rKSHV-HuARLT cells were treated with GA for 2 weeks. Then, GFP expression was determined and the viral copy number per cell was assessed by qPCR. As depicted in Fig. 3a and Fig. S2 , the GA treatment induced substantial viral loss as determined by both readouts. In contrast, treatment of the infected cells with phosphonoformic acid (PhA), an inhibitor of lytically expressed viral DNA polymerase, did not have an effect on the viral copy number and GFP expression. These data support the observation that the cells are predominantly latently infected and lytic reactivation does not play a role in viral maintenance in 2D culture. Several studies indicate that 3D cell culture is beneficial for viral gene expression in lymphatic endothelial as well as in B cells and KSHV-induced cell transformation is more pronounced under these conditions [10, 29] . Therefore, we tested if viral maintenance is better reflected by 3D culture conditions. We observed that after cultivation of cells for 2 weeks under 3D conditions in the absence of selection, the viral load was slightly but significantly higher when compared to standard 2D conditions, with about 10.9 ± 1.12 virus copies per cell in 3D versus 5.5 ± 0.67 in 2D conditions (p = 0.0009). Interestingly, treatment of 3D spheroid cultures with GA but also with PhA resulted in a significant reduction of the viral load (Fig. 3b) . The fact that PhA has an impact on viral copy number suggests that maintenance of virus in 3D conditions involves lytic phases of virus infection and is partially due to viral proteins expressed during the lytic replication cycle.
For evaluation of the invasiveness of KSHV-infected cells upon compound treatment, we adapted a 3D culture system previously described for KSHV-infected primary endothelial cells [10] . rKSHV-HuARLT cells were first aggregated to spheroids and then embedded in a fibrin matrix. Three days after embedding, the KSHV-infected cells exhibited pronounced sprouting and invaded into the surrounding matrix (Fig. 3d) . To validate the specificity of the assay with respect to KSHV, we evaluated the effect of GA, PhA, and rapamycin on sprouting in 3D culture conditions. To that end, the embedded spheroids were treated with the compounds for 5 days. The effect of the compounds was evaluated by microscopy and quantified by measuring the area covered by sprouts and relating it to the spheroid body area in the same section (sprouting index, Fig. S3 ). Quantification revealed a significant reduction of sprouting for GA and rapamycin, which impair viral maintenance and provide anti-angiogenic activity, respectively [5] . In contrast, treatment with the control drugs FK506 and PhA did not reduce the sprouting activity (Fig.  3c) . Together, the three assay systems are appropriate to test compounds for anti-viral and/or anti-tumor activities. Evaluation of novel compounds for viral loss in 2D and 3D culture models
To search for novel anti-KSHV agents that would reduce viral copy number and/or the sprouting of KSHV-infected HuARLT cells, we studied a library of 260 natural compounds. This library mainly consists of secondary metabolites from Myxobacteria that were selected by previous natural product screening programs [30] . We used a previously described reactivation assay in KSHV-infected BJAB cells (Brk.219 cells) [24, 25] to narrow down the list of candidates to be tested in our 3D sprouting assay. We treated Brk.219 cells with the natural compounds in this library and used supernatants from compound-treated reactivated Brk.219 cells to infect HEK 239T cells. Infection rate of HEK 293 was measured via fluorescence microscopy. Figure 4a indicates the compounds that showed reduction of GFP expression in HEK293 cells and therefore inhibited KSHV lytic replication in Brk.219 cells, while at the same time exhibiting low-tomoderate toxicity (Fig. S4 ) in Brk.219 cells. On the assumption that compounds capable of inhibiting lytic KSHV reactivation in Brk.219 cells might do so either because they interfere with the lytic cycle or reduce the number of latent KSHV genomes in this cell line, and since the KSHV lytic cycle is known to contribute to tumorigenesis (reviewed in [31] ), we investigated if compounds with activity in the Brk.219 assay would also reduce the viral load in latently KSHV-infected endothelial HuARLT cells. We selected 26 compounds including pretubulysin D, a chemically accessible precursor of tubulysins [23] . First, we tested their impact on viral copy number in KSHV-infected HuARLT cells using drug concentrations that had little influence on cell viability (> 80% or more viable cells, Fig. S5 and Supplementary Table 1 ). The KSHV latently infected HuARLT cells were cultured in 2D conditions in absence of doxycycline and puromycin and treated with the compounds for 14 days followed by evaluation of viral copy number by qPCR. Out of the 26 compounds tested, seven showed a reduction of the cellular viral load to 75%: epothilone E, myxochelin A, eliamid, saframycin Mx1, stigmatellin F, chondramides B and C (Fig. 4b) . This set of compounds was tested under the more physiologically relevant 3D conditions. To this end, Matrigelembedded spheroids formed from KSHV-infected cells were treated for 14 days with the compounds and then evaluated for the viral copy number per cell. A total of nine compounds were identified that showed a reduction to 60%. In addition to five compounds that already showed positive effects in the 2D assay (epothilone E, myxochelin A, eliamid, chondramides B and C), four compounds showed copy number reductions in 3D culture only: trichangion, pellasoren, tubulysin A, tubulysin X (Fig. 4c) .
To investigate whether the selected compounds have an impact on the cell invasiveness in 3D culture conditions, we evaluated their effect on the cell's sprouting activity. To this end, fibrin gel-embedded spheroids produced from rKSHVHuARLT cells were treated with the compounds for 5 days followed by evaluation of the sprouting index. Overall, 13 compounds significantly reduced sprouting to 60% or less in the 3D sprouting assay, indicating pronounced reduction in the invasive potential of the cells (Fig. 4d) . In Fig. 4e , the results of the three in vitro assays are summarized.
Validation of hits in vivo
We selected four compounds with various degrees of inhibition in the three in vitro test systems, for which pharmacokinetic as well as bioavailability data were available, and investigated their ability to reduce the formation of KS-like lesions in the xenograft model. Chondramid B was chosen as a compound that significantly reduced the viral load in 2D and 3D culture, but with a moderate effect on the sprouting index. In contrast, pretubulysin D and epothilone B were selected for their strong effect on sprouting but no significant effect on the viral copy number. As a drug with minor activities, we selected soraphen A. In addition, we used the mTOR inhibitor rapamycin (and its control FK506) as well as PhA with known anti-viral activities. Starting directly after transplantation of the virus-infected cells, the mice were treated with the respective drugs for 4 weeks. Then, the mice were sacrificed and the plugs were isolated. The lesion size was assessed by microscopy analysis of vimentin-stained sections.
While the control compound FK506 showed no significant effect on tumor size, a certain reduction of lesion size down to about 70-80% of the size of untreated controls was found in mice treated with rapamycin and PhA. Interestingly, a comparable reduction of tumor size was observed for chondramid B and rapamycin which was accompanied by a reduction in viral copy number (Fig. S6) . However, the strongest impairment was observed for epothilone B and pretubulysin D which Fig. 3 rKSHV-HuARLT-based in vitro assays for compound validation. a Mean fluorescence intensity (MFI) and relative viral copy number in rKSHV-HuARLT cells in 2D culture upon treatment with 25 μM glycyrrhizic (GA) or 100 μM phosphonoformic (PhA) acid for 14 days in the absence of puromycin. The experiment was performed two times with comparable outcomes. The graph shows mean and standard deviation in one representative experiment with 3 biological replicates. Statistical significance was determined by t test and is indicated by asterisks, **p ≤ 0.01. b Relative viral copy number in rKSHV-HuARLT cells in 3D culture upon treatment with GA or PhA for 14 days. The experiment was performed two times with comparable outcomes. The graph shows mean and standard deviation in one representative experiment with 3 biological replicates. Statistical significance was determined by t test and is indicated by asterisks, **p ≤ 0.01. c Relative sprouting index upon treatment of rKSHV-HuARLT cells with GA, PhA, rapamycin, or FK506 for 5 days. The graph shows mean and standard deviation of the pooled data from 3 independent experiments with at least 3 biological replicates analyzed in each condition. Statistical significance is indicated by asterisks: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. d Phase contrast and fluorescent microscopy of representative 3D spheroids 5 days after embedding and treatment with GA, PhA, 2.5 μg/ml rapamycin, or 2.5 μg/ml FK506 resulted in a complete regression of the tumor growth (Fig. 5a,  b) . Moreover, the drug-mediated reduction of invasiveness of rKSHV-HuARLT cells in the 3D cell culture conditions strongly correlates with tumor size reduction (R 2 = 0.9266, Fig. 5c ), highlighting the predictive power of the in vitro system with respect to tumor formation in vivo.
Discussion
In this study, we exploited the properties of the previously developed conditionally immortalized human endothelial cell line (HuARLT) [18] upon infection with KSHV. This cell line reflected the consequences of infection on various levels. Similar to cells in Kaposi's sarcoma lesions [11, 12] , the majority of rKSHV-HuARLT cells established latency upon infection with KSHV. Further, their growth critically depended on PI3K/Akt/ mTOR and NF-κB pathways, properties that were shown to provide survival advantage to infected cells [26] . We previously reported that latently-infected HuARLT cells reduce expression of endothelial markers and upregulate mesenchymal markers [18] and thus reflect the endothelial-to-mesenchymal transition observed upon infection of primary human endothelial cells [10] . Finally, infected rKSHV-HuARLT cells gave rise to KS-like lesions upon transplantation into mice, opening the opportunity to investigate the fate of infected cells in vivo. Together, this makes We hypothesized that reduction of viral load within KSHVinfected cells would result in the loss of their tumorigenic potential. This hypothesis is supported by the observation that the viral load within tumor cells correlates with the tumor burden in the patients and reflects the severity of the disease [19] while (at the same time) the plasma level of KSHV is a poor prognostic or diagnostic biomarker for KS [19, 32] . To test this hypothesis, we established a virus-free cell population by passaging rKSHV-HuARLT cells in absence of selection pressure. We observed that indeed, the virus-purged cell population lost their tumorigenic potential upon transplantation in vivo. While establishment of KS-like lesions has also been demonstrated in nude mice with the help of other cell systems [33] [34] [35] [36] , this study confirms that tumorigenicity of the rKSHV-HuARLT cell system is virus-dependent. Thus, viral proteins are essential for inducing the tumorigenic phenotype which is reverted when the cells are depleted from the virus, making this system of particular value for both the investigation of virus-induced tumorigenicity and for the validation of anti-viral compounds specifically acting against KSHV and KSHV-induced tumor formation.
In-depth characterization indicated that the virus established a strictly latent stage in 2D culture and viral maintenance was not affected through blocking the lytically expressed viral DNA polymerase by PhA. In contrast, maintenance of the virus in 3D cell culture at least partially depended on lytic reactivation, as indicated by reduction of viral copy number in presence of PhA. This observation corresponds to recent studies indicating that 3D, but not 2D cell culture conditions support lytic reactivation of the virus [10, 29] and indicates that the 3D cell culture allows validation of the compounds targeting not only latent maintenance, but also lytic replication of the KSHV. 3D sprouting was shown to be useful to study ex vivo angiogenesis [22] as well as the evasion [37] and KSHVinduced invasion of lymph endothelial cells [10] . We showed that impairing viral replication by PhA had only a minor effect on 3D sprouting. In line with this, PhA could also slightly reduce the formation of KS lesions in vivo to a certain extent, although this was statistically not significant. This observation is in line with clinical observations showing that drugs targeting viral lytic replication prevent the formation of KS lesions. Still, inhibitors of lytic replication fail to reduce established lesions and thus may not be suitable for treatment of KS (reviewed in [13] ). This might suggest that inhibition of viral replication alone is not sufficient to block invasiveness of the infected cells and illustrates the limitation of assay systems relying purely on viral copy reduction.
Various viral proteins have been shown to contribute to KSHV-induced invasiveness, including factors expressed in the latent (e.g., LANA [38, 39] , vFLIP [40] , vCyc [41] ) and the lytic (e.g., IL-6 [42] , vGPCR [43] [44] [45] , K1 [46] , K15 [47, 48] ) phase of the viral life cycle. Screening for drugs only according to their ability to reduce KSHV reactivation would thus miss potential KS inhibitors that target KSHV-induced invasiveness and angiogenesis and that would not necessarily affect viral lytic replication. This highlights the need for predictive in vitro screening systems that consider both viral load and cellular invasiveness. Based on KSHV-HuARLT cells, different phenotypic screening systems could be established, which allow investigation of the drugs targeting viral maintenance and affecting in sprouting and angiogenesis.
With the KSHV-HuARLT-based assays, we validated a set of natural compounds and challenged the selected compounds with anti-viral or anti-sprouting activity in a humanized mouse model. As a result, three compounds were identified with comparable or even higher potency to reduce the size of KS lesions than rapamycin, a drug that is in clinical use for KSHV-infected organ transplant recipient with KS. Pretubulysin D and epothilone B were described before as anti-tumor and anti-metastatic agents acting primarily on cellular cytoskeleton [49, 50] . Both compounds drastically reduce sprouting and tumor size in vivo, but have no effect on viral copy number. This suggests that they mainly act via the inhibition of microtubule formation as described previously, rather than targeting pathways relevant for viral maintenance.
In contrast, chondramid B significantly reduced both the viral load in vitro and the tumor size in vivo. The data suggest that the compound might interfere with viral maintenance. Previously, it was shown that chondramid B promotes actin polymerization, thereby also diminishing angiogenesis in vitro and in vivo [51] . It remains to be elucidated if the reduction of viral load by chondramid B depends on its function on actin or is a result of the interaction with other molecular targets. Also, the reduction in tumor size in the presence of chondramid B might not be exclusively attributed to its effect on the virus, but could be a combination of both, the reduction of viral load and deteriorating the nutrition of the tumor by impairing angiogenesis.
Interestingly, while purging the virus from cells could in principle abolish the tumorigenic properties of infected cells, the strongest anti-tumor effect in vivo was observed for pretubulysin and epothilone which have a direct antiproliferative and anti-angiogenic effect. This might suggest that reduction of viral load alone has a limited therapeutic potential but might be more efficient as a part of combined anti-tumor and anti-viral therapies. However, more compounds as well as combination protocols would need to be evaluated to draw a general conclusion. Of note, in this study, we investigated effects of anti-KSHV treatment applied together with the transplantation of the infected cells, which does not reflect a course of tumor development in patients. Evaluating the performance of the drugs on preexisting KSHV-induced tumors will allow the assessment of the drugs in clinical-like situations. The mouse model we introduce here would be of particular benefit for such advanced studies.
Animal tests play a crucial role in drug development, because they not only allow the confirmation of selective drug activity, but also assess its pharmacokinetics, pharmacodynamics, toxicity, and safety in vivo. Humanized mouse models expand the toolbox and allow us to study human-specific diseases, like Kaposi's sarcoma, as well. In this regard, advanced and predictive in vitro systems can improve drug development by providing meaningful tools for screening of large compound libraries in vitro and prevalidating the performance, thereby reducing the amount of required experimental animals and lowering the costs of drug development.
Our findings highlight the potential of the assay system to identify compounds that target pathways relevant for supporting viral latency in vitro and to evaluate the reduction of tumor growth in vivo established from the same cell line. Since the combined use of anti-viral and anti-tumor assays is indicative for anti-tumor activity in vivo, it has the potential for faithful pre-selection of active compounds in vitro to reduce the number of experimental animals and ensure compliance with 3R principles, i.e., the replacement of animal experiments, reduction amount of animals used, and refinement of experimental conditions.
